SUBSCRIBE
SUBSCRIBE
News   Business

Roche Holding AG Said to Return Diabetes Drug Rights to Ipsen Because of Side Effects

February 1, 2011 | 
1 min read
Bloomberg -- Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.
Alliances
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Dashed line from pills isolated on white
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
April 24, 2026
 · 
2 min read
 · 
Tristan Manalac
IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch
IPO tracker
Avalyn seeks public debut to support new lung drug formulations
April 24, 2026
 · 
11 min read
 · 
Editorial Team
Illustration of two arrows merging into one
Deals
Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership
April 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business people run on the arrows. Business concept of competition or target aiming. Flat vector illustration.
Leadership
BBOT shakes up leadership as RAS competitors get more visibility
April 23, 2026
 · 
2 min read
 · 
Annalee Armstrong